TC Biopharm announces transition to OTC Markets from Nasdaq
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 21 2025
0mins
Delisting from Nasdaq: TC BioPharm has been notified that its securities will be delisted from Nasdaq due to non-compliance with the minimum bid price requirement of $1.00 per share, effective March 24, 2025.
Appeal and OTC Trading: The company is appealing the decision and expects its American Depositary Shares to begin trading on the OTC Markets starting March 24, 2025.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
